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ABSTRACT
A 51-year-old man was admitted due to an acute anterior ST-segment elevation myocardial infarction. After thrombolytic 
therapy using recombinant tissue plasminogen activator, stent implantation was performed from the proximal left anterior de-
scending artery (LAD) to the mid LAD using a bare-metal stent (BMS). Since then, the patient suffered five repeated epi-
sodes of in-stent restenosis (ISR). At the first ISR, he was treated with plain old balloon angioplasty (POBA). At the second 
ISR, he was treated with brachytherapy, and at the third ISR, he was treated with POBA and one more BMS distal to the pre-
viously implanted stent. At the forth, only POBA was performed, and finally, at the fifth ISR, a sirolimus-eluting stent was 
implanted. Following that, the patient remained asymptomatic and follow-up coronary angiography showed no ISR. (Kore-
an Circ J 2011;41:677-680)
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Introduction
Stents reduce clinical and angiographic restenosis com-
pared to conventional balloon angioplasty.
1) However, in a 
number of patients with implanted stents, neointimal hyper-
plasia produces in-stent restenosis (ISR).
2) Although often 
considered a benign process, recent data reveals that ISR has 
a negative impact on long-term survival.
3) In fact, repeated 
procedures have been associated with a higher risk of myo-
cardial infarction and stent thrombosis.
4) Vascular brachyth-
erapy was the approved therapy, in comparison with balloon 
angioplasty,
5)6) but recent studies suggest that drug-eluting 
stents (DES) may be superior to brachytherapy.
7)8) We experi-
enced one intractable ISR case which repeated regardless of 
successful brachytherapy treatment, and which was treated us-
ing DES.
Case
On February 2000, a 51-year-old man was admitted to the 
hospital with an acute anterior ST-segment elevation myo-
cardial infarction. His electrocardiogram (ECG) showed ST-
segment elevation in V1-5. After thrombolytic therapy using 
recombinant tissue plasminogen activator, stent implanta-
tion was performed from the proximal left anterior descend-
ing artery (LAD) to the mid LAD using 3.0×27 mm bare-me-
tal stent (BMS) as an elective percutaneous coronary inter-
vention (Fig. 1).
One year later, recurrent chest pain developed and an ECG 
showed ST-segment elevations in V1-5. Coronary angiogra-
phy (CAG) revealed type IV (total) ISR in the proximal LAD, 
which was treated with balloon angioplasty using a 3.0×20 
mm balloon (the first ISR). One year after that, recurrent 
chest pain developed, and ECG showed no ST-T changes, but 
CAG revealed type II (diffuse) ISR. This second ISR was treat-678   DES for In-Stent Restenosis
ed with brachytherapy with a Rhenium filled balloon (300 se-
conds at 6 atm using a 3.0×20 mm balloon) (Fig. 2). 
Four months later, recurrent chest pain developed once ag-
ain and an ECG showed ST-segment elevations in V1-4. CAG 
revealed type IV ISR secondary to brachytherapy failure, 
which was treated with 3.0×20 mm balloon and 3.0×18 mm 
Fig. 1. A diagnostic coronary angiogram (CAG) revealed successful thrombolysis status but a critical stenosis of the proximal and mid left 
descending artery. After successful stent implantation using a 3.0×27 mm bare-metal stent, final CAG showed no residual stenosis with 
good distal flow.
Fig. 3. Third in-stent restenosis (ISR). A coronary angiogram (CAG) revealed type IV ISR secondary to brachytherapy failure. Plain old bal-
loon angioplasty using a 3.0×20 mm balloon and 3.0×18 mm bare-metal stent implantation distal to previously implanted stent was per-
formed. Final CAG showed no residual stenosis with good distal flow.
Fig. 2. Second in-stent restenosis (ISR). A coronary angiogram (CAG) revealed type II ISR. Brachytherapy with Rhenium was performed 
for 300 seconds at 6 atm using a 3.0×20 mm balloon. Final CAG showed no residual stenosis with good distal flow.Daisuke Hachinohe, et al.   679
BMS implantation distal to the previously implanted BMS 
(the third ISR) (Fig. 3). Three months later, chest pain recurr-
ed and ECG showed ST-segment elevations in V3-5. CAG 
revealed type II ISR, which was treated with only ballooning 
(the fourth ISR). Nine months later, recurrent chest pain de-
veloped, and ECG showed no ST-T changes. CAG revealed 
type II ISR in the proximal and mid LAD stent. A 3.0×33 mm 
Cypher stent
® (Cordis Johnson & Johnson, Bridgewater, NJ, 
USA) was implanted to treat this fifth ISR presentation (Fig. 
4). The patient then remained asymptomatic and the 5-year 
follow-up CAG showed no ISR (Fig. 5).
Discussion
Bare-mental stent has improved procedural success and long-
term outcomes, and reduced clinical and angiographic reste-
nosis compared to plain old balloon angioplasty (POBA).
1)9) 
Although stenting can resolve elastic recoil, negative remodel-
ing and dissection caused by POBA and neointimal hyper-
plasia produces ISR in 20% to 50% of the patients implanted 
stent.
2)10) ISR is often considered to be a benign process, but a 
recent report showed that it presents with acute myocardial 
infarction or unstable angina in over one-third of cases
3) and 
has a negative impact on long-term survival.
11) In fact, repeat-
ed procedures have been associated with a higher risk of myo-
cardial infarction and stent thrombosis.
4)
There are many treatment options for ISR. Although PO-
BA is the first-line option, its results have been disappoint-
ing. Repeated use of BMS also exacerbates the risk of recur-
rence. Coronary artery bypass surgery may be an option for 
the treatment of recurrent ISR after BMS implantation. Al-
ternative options, such as rotational atherectomy, excimer la-
ser angioplasty, and cutting balloon did not reduce recurrent 
ISR.
12)
Several reports show the efficacy of brachytherapy in pa-
tients with ISR,
5)6)13)14) but brachytherapy presents problems 
such as logistical complexity, expense, and durability.
12) Re-
cent studies suggest that DES is superior to POBA,
8)15) and 
moreover DES may even be superior to brachytherapy.
7)8) 
This is a unique case for the successful management of in-
tractable ISR with DES, even after POBA, BMS and brachy-
therapy. 
In conclusion, we experienced an intractable ISR case, 
which can be treated by using DES. As recent studies show, 
DES is the best treatment option for ISR, and may even be 
used successfully to treat brachytherapy failure and intracta-
ble ISR. 
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